Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 35 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/23/2006 First Published: 4/1/2000


1.		Phase III Randomized Study of Sargramostim (GM-CSF) and Peptide Vaccination Comprising Tyrosinase:368-376, gp100:209-217 (210M) Antigen, and MART-1:27-35 Peptide Versus Peptide Vaccination Alone Versus GM-CSF Alone Versus Placebo in Patients With Locally Advanced or Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				ECOG-4697 SWOG-E4697, E4697, NCT00005034

Last Modified: 6/8/2006 First Published: 5/1/2002


2.		Phase III Randomized Study of Adjuvant NA17-A and Melanoma Differentiation Peptides in HLA-A2-Positive Patients With Primary Ocular Melanoma at High Risk of Relapse

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Over 18				Other				EORTC-18001 EORTC-88001, NCT00036816

Last Modified: 8/10/2006


3.		Phase I/II Study of Immunization With Dendritic Cells Presenting Epitopes Derived from the Melanoma Associated Antigens MART-1 and gp100 With or Without Interleukin-2 in Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NCI-97-C-0046 NCI-97-C-0019, NCI-T96-0046N, T96-0046, NCT00019214

Last Modified: 2/1/2002


4.		Phase I/II Study of Immunization with MAGE-3 or Melan-A Peptide-Pulsed Autologous Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 in Patients with Metastatic Melanoma (Summary Last Modified 02/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				Not specified				NCI				UCCRC-9018 UCCRC-8381, NCI-G97-1162, NCT00002952

Last Modified: 7/1/2002 First Published: 2/1/2001


5.		Phase I/II Study of Ad2/MART-1v2 and Ad2/gp100v2 Melanoma Antigen Vaccines in Patients With Stage II, III, or IV Melanoma (Summary Last Modified 07/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				GENZ-ADVMEL-001-99 DFCI-00069, GENZ-2000-P-000380/1, NCT00010309

Last Modified: 8/31/2006 First Published: 1/1/1998


6.		Phase II Study of Immunization Comprising Immunodominant Peptides from 3 Melanoma Antigens (MART-1, gp100, and Tyrosinase) in Patients With Refractory Metastatic Melanoma (Summary Last Modified 10/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				NCI-98-C-0023 NCI-T97-0089, T97-0089

Last Modified: 9/1/2002 First Published: 3/1/1998


7.		Phase II Study of Flt3 Ligand Alone or in Combination With Melanoma Peptide Immunization in Patients With Metastatic Melanoma or Renal Cell Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Not specified				NCI				NCI-98-C-0040 NCI-T97-0092, T97-0092, NCT00019396

Last Modified: 6/5/2003 First Published: 6/1/1999


8.		Phase II Study of MART-1 and gp100 Peptides Modified to Increase Binding to HLA-A0201 With or Without Interleukin-2 in Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				NCI-99-C-0092 NCI-T99-0033, T99-0033, NCT00019721

Last Modified: 11/12/2007 First Published: 12/1/1999


9.		Phase II Study of Immunization Using gp100:44-59, gp100:209-217 (210M), and MART-1:26-35 (27L) Antigen Peptides in HLA-DRB1*0401 Positive Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				NCI-99-C-0159 NCI-T99-0079, T99-0079, NCT00019994

Last Modified: 6/27/2006 First Published: 8/1/2000


10.		Phase II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides From MART-1:26-35, gp100:209-217, and Tyrosinase:368-372 and Treated Ex Vivo With CD40-Ligand and Interferon Gamma, Followed By Interleukin-2 In Vivo in HLA-A2.1 Positive Patients With Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				LAC-USC-10M991 NCI-G00-1837, NCI-T99-0102, NCT00006113, T99-0102

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute